Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel
Study examines effects of higher NSAIDs dosages
Researchers test if higher doses alleviate foot pain in horses

A study carried out by researchers in America has examined whether higher-than-standard doses of non-steroidal anti-inflammatory drugs (NSAIDs) alleviate foot pain more efficiently.

To test this hypothesis, Jonathan Foreman DVM, MS, Dipl. ACVIM and his colleagues at the University of Illinois at Urbana-Champaign used a reversible heart bar shoe to allow sound horses to become temporarily lame. The pain subsides completely when researchers loosen the screw in the shoe to relieve foot pressure.

When the researchers tighten the screw in the shoe the pain level increases, as reflected by increasing heart rates. Following the regional anaesthesia application, the horses' heart rates dropped from 60 to 40 beats per minute (bpm).

In this study the scientists compared the effects of varying intravenous doses (half-dose, 1x, 2x) of flunixin meglumine; they used saline as a control. Ten sound horses wore a reversible heart bar shoe on the front left foot. Following treatment, the 1x and 2x doses improved heart rates for the 12-hour duration, whereas heart rates remained elevated in the control horses.

Heart rates in the horses given half-doses of flunixin did not decrease as much as those in the 1x and 2x horses, and they didn't remain low for as long. "They responded intermittently and not as obviously," Foreman commented. There was no difference in heart rate results between the horses receiving 1x or 2x flunixin meglumine.

Foreman concluded that the double dose was no more effective than the single dose and presented a higher risk of toxicity. The half-dose was less effective than the single dose; therefore, you can't rely on an anti-endotoxic half-dose to provide complete pain control for horses with painful hoof conditions such as laminitis.

Foreman summed the study up by saying: "More is not better and less is less effective."


Become a member or log in to add this story to your CPD history

Strangles survey seeks views of horse owners

News Story 1
 With Strangles Awareness Week just around the corner (5-11 May), vets are being encouraged to share a survey about the disease with their horse-owning clients.

The survey, which has been designed by Dechra, aims to raise awareness of Strangles and promote best practices to prevent its transmission. It includes questions about horse owners' experiences of strangles, together with preventative measures and vaccination.

Respondents to the survey will be entered into a prize draw to win two VIP tickets to Your Horse Live 2025. To access the survey, click here 

Click here for more...
News Shorts
DAERA to reduce BVD 'grace period'

DAERA has reminded herd keepers of an upcoming reduction to the 'grace period' to avoid BVD herd restrictions.

From 1 May 2025, herd keepers will have seven days to cull any BVD positive or inconclusive animals to avoid restrictions being applied to their herd.

It follows legislation introduced on 1 February, as DAERA introduces herd movement restrictions through a phased approach. Herd keepers originally had 28 days to cull BVD positive or inconclusive animals.

DAERA says that, providing herd keepers use the seven-day grace period, no herds should be restricted within the first year of these measures.

Additional measures, which will target herds with animals over 30 days old that haven't been tested for BVD, will be introduced from 1 June 2025.

More information is available on the DAERA website.